Ferring Bravelle approved
Executive Summary
Ferring's Bravelle (urofollitropin) clears FDA May 6 for use in conjunction with human chorionic gonadotropin "for ovulation induction in patients who have previously received pituitary suppression." The intramuscular/subcutaneous injectable will be the third human-derived follitropin on the market, joining Serono's Fertinex (urofollitropin) and Pergonal (menotropins). Bravelle will be available in mid-May, Ferring said. The company has a pending NDA for use of Bravelle in in-vitro fertilization...
You may also be interested in...
Bravelle approval (correction)
Ferring's Bravelle (urofollitropin) is the fourth human-derived gonadotropin on the market, following Serono's Fertinex (urofollitropin) and Pergonal (menotropins), and Ferring's Repronex (menotropins). Bravelle and Fertinex are follitropins, while Pergonal and Repronex are not (1"The Pink Sheet" May 13, In Brief)...
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.